ライフサイエンスコーパス: antisense

1 an ethylene-deficient transgenic line, ACS2-antisense.

2 aracterized long noncoding RNA (lncRNA), SMN-antisense 1 (SMN-AS1), represses SMN2 expression by recr

3 in the consensus two-directional (sense and antisense) "2D" sequences were first characterized by wa

4 ys will aid in the design of next generation antisense agents with improved therapeutic properties.

5 Sense and antisense Alu elements fold independently of one another

6 ently for complementation, overexpression or antisense analysis, but sequence changes caused by callu

7 nstrated by the beneficial effect of Cavbeta antisense and gabapentin in allergic airway inflammation

8 reveals a variety of RNAs including numerous antisense and intragenic transcripts, leaderless RNAs, l

9 ing cassettes were constructed around sense, antisense and non-translatable-stop strategies (pGRsense

10 ms at different stages of meiosis, including antisense and read-through transcripts.

11 Antisense and RNAi-based gene-knockdown methods vary in

12 A cross between the SlFRK2-antisense and SlFRK3-RNAi lines exhibited similar wiltin

13 o complementary miRNAs (sense miRNA-122, and antisense antimiR-21) encapsulated in biodegradable poly

14 ions cause retinal degeneration, and show an antisense approach can correct disease-associated phenot

15 ased therapies, antibiotic potentiators, and antisense approaches.

16 ss the entire SNORD27 sequence, not just the antisense boxes.

17 population of Tax-expressing cells exhibited antisense but not activated sense transcription.

18 ing/modification factors are dispensable for antisense, but not sense, transcription of GAL10.

19 RAN translation from antisense CCG repeats generates novel proteins that accu

20 a rather new class of molecule based on the antisense concept.

21 isms, with the majority of transcripts being antisense copies of proviruses located within introns.

22 sites can arise at differing frequencies in antisense depending on the overlapping transcript type.

23 fore open new pathways for research into the antisense, diagnostic, and nanotechnology oligonucleotid

24 However in the antisense direction, predicted binding sites occur at hi

25 ription in both forward (sense) and reverse (antisense) directions.

26 ctly (p <0.0001) detect the origin (sense vs antisense DNA strands) of DNA methylation at splice site

27 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular

28 tment with volanesorsen, a second-generation antisense drug targeting apoC-III, were determined in 2

29 or their delivery, and the current status of antisense drug therapy clinical trials for gastrointesti

30 involved in pre-mRNA to mRNA maturation with antisense drugs can lead to efficient gene silencing and

31 ively decreased production of both sense and antisense expanded transcripts, as well as their transla

32 Treatment of the wild type and ACS2-antisense fruit with the ethylene-signaling inhibitor, 1

33 lso deregulated in 42% of the observed sense-antisense gene pairs.

34 his finding also makes it possible to assess antisense gene regulation efficiency of these brush-DNA

35 which maps to the RP11-634B7.4 gene, a novel antisense gene to three olfactory receptor genes.

36 genes, leading to a marked increase in their antisense-generating potential.

37 The majority of the antisense genes had a similar effect sizes in an indepen

38 Sense genes expressed opposite of these antisense genes were also deregulated in 42% of the obse

39 re detected, 257 of which were classified as antisense genes.

40 intermediates that license transcription of antisense genomic viral RNAs.

41 s obtained after deletion of Haglr, the Hoxd antisense growth-associated long noncoding RNA (lncRNA)

42 domain of the RNA editing enzyme ADAR to an antisense guide RNA, specific adenosines can be converte

43 Although CD44 antisense has no effect on the hyperalgesia induced by i

44 One group of lncRNAs, which are antisense in orientation to coding mRNAs (ASs), have bee

45 ITD(+) AML samples using locked nucleic acid antisense inhibitors, results in an elevated IFN respons

46 neurodegenerative disease associated with an antisense insertion of a SINE-VNTR-Alu (SVA)-type retrot

47 es, the barriers to oral-based therapies and antisense-interfering technologies, the approaches that

48 ding RNA (lncRNA) HOTAIR (for HOX Transcript Antisense Intergenic RNA) mediates a physical interactio

49 Antisense knockdown of NR4A2 and NR4A3 homologs in zebra

50 Antisense knockdown of slincR results in an increase in

51 Using antisense knockdown of the n1-src microexon, we have stu

52 the sense protein-coding transcript and the antisense lncRNA increase dramatically in sporozoites.

53 of structural and sequence components of the antisense lncRNA.

54 og (PTEN) pseudogene as a model system, that antisense lncRNAs interact first with a 5' UTR-containin

55 ic variation in 5' end precision, occasional antisense loci, and putatively noncanonical loci.

56 te also correlates with the expression of an antisense long non-coding RNA (lncRNA) that has previous

57 tion as distantly-acting control elements of antisense long non-coding RNAs, which in turn regulate t

58 highlight that together with coding genes, (antisense) long non-coding RNAs are deregulated in skin

59 Knockdown (KD) of AGO2, or antisense-mediated depletion of Let-7, caused Ccnd1 tran

60 Acute, antisense-mediated liver FA binding protein knockdown in

61 ligonucleotides (SSOs) are short, synthetic, antisense, modified nucleic acids that base-pair with a

62 Using splice site-specific antisense morpholino oligos, we inhibited n1-src splicin

63 ss-of-function assays (via microinjection of antisense morpholino or CRISPR-Cas9) confirm that AChE i

64 y, knockdown of zebrafish otg using specific antisense morpholino promoted nuclear accumulation of be

65 Loss of function of beta-catenin with antisense morpholinos reproducibly reduced the expressio

66 Depletion of keratin (krt8) with antisense morpholinos results in high traction stresses

67 Here we show that circular antisense non-coding RNA in the INK4 locus (circANRIL),

68 erosis pathogenesis with a specific focus on antisense non-coding RNAs.

69 susceptibility locus that encodes the lncRNA antisense noncoding RNA in the INK4 locus (ANRIL).

70 SP gene suppression in both wild-types, ACS2-antisense, nor/nor and Nr/Nr, but not the rin/rin mutant

71 Knockdown of CREB with antisense oligodeoxynucleotide against CREB reduced mech

72 pha bioactivity) or knockdown of TNFRI using antisense oligodeoxynucleotide against TNFRI reduced mec

73 eatment of GN mice with connexin 43-specific antisense oligodeoxynucleotide improved functional and s

74 ter intrathecal injection of a gene-specific antisense oligodeoxynucleotide to knock down the express

75 GED-0301 is an antisense oligodeoxynucleotide with a sequence complemen

76 Escherichia coli, we have developed a short antisense oligomer designed to inhibit the expression of

77 The sensitizing effect of the antisense oligomer is highly specific to the targeted ge

78 Finally, we demonstrate that antisense oligomers improve the efficacy of antibiotic c

79 Systemically administered antisense oligonucleotide (ASO) inhibited miR-182 in the

80 ted with disease following treatment with an antisense oligonucleotide (ASO) targeted to the site of

81 We identified an exon 11 antisense oligonucleotide (ASO) that increased lamin C p

82 For this study, we compared a novel Gen 2 antisense oligonucleotide (ASO) that inhibits angiotensi

83 many as a half million components persist in antisense oligonucleotide (ASO) therapeutics because it

84 Antisense oligonucleotide (ASO) therapeutics show tremen

85 We utilize an antisense oligonucleotide (ASO) to reduce apoE expressio

86 pivotal proof of principle that therapeutic antisense oligonucleotide (ASO) treatment can effectivel

87 We used an antisense oligonucleotide (ASO)-based inducible mouse mo

88 We have previously reported on an antisense oligonucleotide (ASO-29) that dramatically imp

89 a mixed modality approach combining an Xist antisense oligonucleotide and a small-molecule inhibitor

90 Three participants who received the antisense oligonucleotide and three who received placebo

91 ect of IONIS-APO(a)-LRx, a ligand-conjugated antisense oligonucleotide designed to be highly and sele

92 Nusinersen is an antisense oligonucleotide drug that modifies pre-messeng

93 d elements involved in mRNA processing using antisense oligonucleotide drugs can be used as a strateg

94 Antisense oligonucleotide knockdown of hepatic ASS1 expr

95 PSC-derived human cortical neurons following antisense oligonucleotide knockdown.

96 Targeting tRNA(Arg)(UCU) with an antisense oligonucleotide replicated effects of Hili and

97 ive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a si

98 pendent clinical trials with drisapersen, an antisense oligonucleotide targeting exon 51: an open lab

99 An intrathecally delivered antisense oligonucleotide that aims to lower huntingtin

100 Custirsen is a second-generation antisense oligonucleotide that inhibits clusterin produc

101 X011) is a second generation highly specific antisense oligonucleotide that inhibits the production o

102 The only approved SMA treatment is an antisense oligonucleotide that targets the intronic spli

103 The development of antisense oligonucleotide therapy is an important advanc

104 uppressing MdMYB39L expression in pollen via antisense oligonucleotide transfection significantly red

105 t the combinatorial effect of suboptimal SMN antisense oligonucleotide treatment and PLS3 overexpress

106 In just the past 5 years, over 100 antisense oligonucleotide-based therapies have been test

107 atient-derived xenograft (PDX) mouse models, antisense oligonucleotide-mediated (ASO-mediated) skippi

108 geting mast cells in vitro and in vivo using antisense oligonucleotide-mediated exon skipping of the

109 binding sites based on insensitivity to DNA antisense oligonucleotide-mediated RNase H digestion.

110 Previously, we showed that naked antisense oligonucleotides (AONs) effectively restored n

111 Antisense oligonucleotides (AONs) were designed specific

112 Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the

113 gene-specific method of NMD inhibition using antisense oligonucleotides (ASOs) and combine this appro

114 hods to suppress expression of mRNAs include antisense oligonucleotides (ASOs) and RNA interference (

115 Antisense oligonucleotides (ASOs) and RNA-interference a

116 Antisense oligonucleotides (ASOs) are an established too

117 RNase H1-dependent antisense oligonucleotides (ASOs) are chemically modifie

118 Antisense oligonucleotides (ASOs) are often used to down

119 Antisense oligonucleotides (ASOs) are small sequences of

120 Antisense oligonucleotides (ASOs) are versatile tools th

121 The ability to control gene expression with antisense oligonucleotides (ASOs) could provide a new tr

122 Antisense oligonucleotides (ASOs) designed to serve as s

123 Here, we show that antisense oligonucleotides (ASOs) effectively suppress P

124 Phosphorothioate (PS)-modified antisense oligonucleotides (ASOs) have been extensively

125 c loss or systemic knockdown of Malat1 using antisense oligonucleotides (ASOs) in the MMTV (mouse mam

126 Targeted degradation of SMN-AS1 with antisense oligonucleotides (ASOs) increases SMN expressi

127 Here we show that systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice effic

128 Antisense oligonucleotides (ASOs) modified with phosphor

129 We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 mess

130 Single-dose injection of antisense oligonucleotides (ASOs) that target repeat-con

131 y showed that translation can be enhanced by antisense oligonucleotides (ASOs) that target upstream o

132 The available strategies include the use of antisense oligonucleotides (ASOs) to alter splicing or k

133 ng approach to treat DM1 uses DMPK-targeting antisense oligonucleotides (ASOs) to reduce levels of to

134 this issue of the JCI, successfully utilized antisense oligonucleotides (ASOs) to reduce PMP22 and am

135 Antisense oligonucleotides (ASOs) with phosphorothioate

136 ll-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic m

137 In this study, using splice-switching antisense oligonucleotides (ASOs), we increased the synt

138 directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs).

139 scular dystrophy (DMD), employing morpholino antisense oligonucleotides (PMO-AO) to exclude disruptiv

140 r functional inhibition by sequence-specific antisense oligonucleotides allows the unprecedented telo

141 hip between in vivo inhibition of miR-182 by antisense oligonucleotides and improved post-injury kidn

142 Huntingtin-lowering strategies include antisense oligonucleotides and RNA interference targetin

143 Antisense oligonucleotides are not a new concept, but su

144 lly in areas of myofiber regeneration, where antisense oligonucleotides are stored in macrophages and

145 cacy, safety, and tolerability of two unique antisense oligonucleotides designed to lower Lp(a) conce

146 o its first human clinical trial, with other antisense oligonucleotides expected to enter trials in t

147 hermore, delayed administration of periostin antisense oligonucleotides in wild-type animals with GN

148 iated delivery of phosphorothioated TRAF3IP2 antisense oligonucleotides into the LV in a clinically r

149 Antisense oligonucleotides linked by phosphorothioates a

150 Antisense oligonucleotides may be coupled to high-affini

151 Knock-down of InsP3R1 expression by antisense oligonucleotides or knock-down or knock-out of

152 peptide-phosphorodiamidate morpholino (PPMO) antisense oligonucleotides that induced temporary dystro

153 d on a modular hybrid minigene combined with antisense oligonucleotides to enable verification of fun

154 We used Cavbeta antisense oligonucleotides to knock down Cavbeta and gab

155 Antisense oligonucleotides were designed based on the se

156 When C9ORF72 was overexpressed or antisense oligonucleotides were targeted to the C9orf72

157 lly manipulated CD46 exon 13 inclusion using antisense oligonucleotides, opening up opportunities for

158 the RNA-binding protein Nanos2 by morpholino antisense oligonucleotides, or knockout of the Nanos2 ge

159 CRISPR/Cas9 or by knocking down UBE3A using antisense oligonucleotides.

160 es are mainly induced by chemically modified antisense oligonucleotides.

161 cer therapy, we here report the synthesis of antisense-oligonucleotides (ASO) and thyroid hormone T3

162 The antisense oligos of FOXD3-AS1 significantly augmented th

163 ic banana plants repressing either gene (via antisense or RNA interference [RNAi]) were created and e

164 Oligonucleotide therapeutics, such as antisense or Transcription Factor Decoys (TFDs), have th

165 The majority of expression was in the antisense orientation and from proviruses integrated wit

166 ermine their combined activities, and in the antisense orientation to measure enhancer activities alo

167 l conserved long noncoding RNAs expressed in antisense orientation to myocardial transcription factor

168 NG12-AS1, a nuclear lncRNA transcribed in an antisense orientation to the tumour-suppressor DIRAS3.

169 ulating the self-regulatory circuit of sense-antisense pairs and the exon skipping during alternative

170 NAs can work as regulatory agents beyond the antisense paradigm and that, hence, they could be interf

171 These observations were confirmed by using antisense paradigms.

172 We show that antisense promoter transcription is generally dependent

173 ts in favor of the in vivo expression of the AntiSense Protein (ASP) of HIV-1.

174 ns, astrocytes, and glia in gray matter, and antisense QAGR proteins accumulate within white matter.

175 A PARTICLE (Gene PARTICL- 'Promoter of MAT2A-Antisense RadiaTion Induced Circulating LncRNA) partakes

176 Cavbeta antisense reduces T-cell receptor-driven calcium respons

177 approaches that require targeting sense and antisense repeats separately.

178 iption factors to binding sites in Tsix, the antisense repressor of XCI.

179 ally induced endogenous Xist by ablating the antisense repressor Tsix in mice.

180 Parallel to Has2 mRNA, Has2 antisense RNA (Has2os2) was up-regulated in co-cultures.

181 that the long non-coding RNA HOX transcript antisense RNA (HOTAIR) is overexpressed in pancreatic ca

182 r region drive the overexpression of a novel antisense RNA and contribute to the development of lymph

183 similarly decreased production of sense and antisense RNA foci, as well as DPR proteins, in patient

184 strand and the relative chance of degrading antisense RNA in the other strand-in the same regions of

185 Our results provide direct evidence that L1 antisense RNA plays a functional role in chromosome-wide

186 egrations driving overexpression of the TERT antisense RNA suggest it may have a role in tumorigenesi

187 t al that proposes regulating Wilm's tumor-1 antisense RNA to control pathological bone resorption.

188 n-coding RNA (lncRNA) HOTAIR (HOX transcript antisense RNA) have diverse functional roles in cancer.

189 studies of the lncRNA HOTAIR (HOX transcript antisense RNA) provide compelling evidence for therapeut

190 romoter for the transcription of a noncoding antisense RNA, asDOG1, that is 5' capped, polyadenylated

191 genetic tools, along with optimized RBSs and antisense RNA, we engineered B. marmarensis to produce e

192 Conversely, antisense RNA-mediated attenuation of SIRT2 reversed ROS

193 s this, we demonstrate how naturally derived antisense RNA-mediated transcriptional regulators can be

194 , in most cases, not associated with a known antisense RNA.

195 transcript appears to be an uncharacterized antisense RNA.

196 quences spliced to exons 4 through 7 of this antisense RNA.

197 replication cohorts, respectively] and PROX1-antisense RNA1 (PROX1-AS1: rs1891059, P = 2.28 x 10(-7)

198 em from Streptococcus pyogenes and synthetic antisense RNAs (asRNAs) in Escherichia coli strains to r

199 Current approaches to design efficient antisense RNAs (asRNAs) rely primarily on a thermodynami

200 turely terminated RNAs (ptRNAs) and upstream antisense RNAs (uaRNAs).

201 ivo, but it is unknown whether the resultant antisense RNAs are a mechanistic by-product of RNA polym

202 siae, results in transcription initiation of antisense RNAs embedded within body of protein-coding ge

203 ng to protein-coding genes, long ncRNAs, and antisense RNAs were due to DNA contamination on the surf

204 m can be created through engineering minimal antisense RNAs.

205 old to over 900-fold, in response to cognate antisense RNAs.

206 we used a pairwise partial loss of function antisense screen for embryonic brain morphology, using t

207 Our work highlights that antisense small RNAs can work as regulatory agents beyon

208 that promotes base pairing between the FinP antisense sRNA and the traJ mRNA to control F plasmid tr

209 r fusion leads to the generation of abundant antisense sRNAs that map to the target gene, with silenc

210 iRAPs encoded in the antisense strand also promote gene expression by reducin

211 We demonstrate that the sense and antisense strand DNA mutagenesis at the immunoglobulin h

212 The distribution of sense and antisense strand DNA mutations on transcribed duplex DNA

213 chromosome-wide effects of ASAR6 map to the antisense strand of an L1 retrotransposon within ASAR6 R

214 HTLV-1 encodes a protein from the antisense strand of its proviral genome, the HTLV-1 basi

215 non-coding RNA (lncRNA) that arises from the antisense strand of SMN, SMN-AS1, which is enriched in n

216 The antisense strand of the HTLV-2 proviral genome also enco

217 Targeting the antisense strand of the L1 within ectopically expressed

218 This putative protein is encoded on the antisense strand of the provirus genome and entirely ove

219 s approach is complicated by the presence of antisense strand transcription of expanded GGCCCC repeat

220 The HTLV genome antisense-strand genes hbz and aph-2 are often the only

221 ral C4'alpha-epimer monomers in the sense or antisense strands triggered RNAi-mediated gene silencing

222 ly, a new wave of clinical studies exploring antisense strategies is evolving.

223 on was noticed, identifying good targets for antisense strategies.

224 Here we used an antisense strategy to knock down GLT-1 or xCT in the nuc

225 Our results suggest that antisense TE transcription is a "trap" that elicits an e

226 ne expression or to modify RNA splicing, but antisense technology has not previously been used to dir

227 of USH1C and reveal the potential for using antisense technology to treat vestibular dysfunction.

228 e DM2 CCTGCAGG expansion expresses sense and antisense tetrapeptide poly-(LPAC) and poly-(QAGR) RAN p

229 Novel antisense therapies targeting apolipoprotein C-III (for

230 revented by intrathecal oligodeoxynucleotide antisense to CD44 mRNA, which also prevents hyperalgesia

231 Here we used antisense to decrease the expression of GLT-1 and xCT (a

232 Antisense to EsRalpha prevented the induction of priming

233 Treatment of female rats with antisense to estrogen receptor alpha (ERalpha), but not

234 Furthermore, a long non-coding RNA antisense to FOXM1 (FOXM1-AS) promotes the interaction o

235 us), as well as 402 spliced lncRNAs that are antisense to protein-coding (PC) genes.

236 (RS2) in the short repeat region, partially antisense to RS1.

237 When inserted sense or antisense to the luciferase reading frame, the XDP varia

238 ALT is expressed antisense to the major viral latency transcripts encodin

239 The antisense-to-latency transcript (ALT) lncRNA was discove

240 Furthermore, the density of antisense transcribing polymerase upstream of the promot

241 E3A allele is repressed by an extremely long antisense transcript (UBE3A-ATS).

242 we characterize a broadly expressed natural antisense transcript at the MALAT1 locus, designated as

243 sense transcripts and initiation of a novel antisense transcript downstream of the sgRNA/dCas9-bindi

244 n convergent genes lead to starkly different antisense transcript landscapes between budding and fiss

245 Furthermore, an antisense transcript overlapping with the BBC3 gene (als

246 RNA sequencing, we identified 1769 sense and antisense transcript pairs (NAT pairs) in two maize inbr

247 4.32 x 10-10 for the meta-analysis) in novel antisense transcript RP11-206M11.7;rs146091982 (beta = 0

248 , the long-noncoding RNA PEAT (Pax1 enhancer antisense transcript) was induced in sclerotome-directed

249 intergenic RNA, small nucleolar RNA, natural antisense transcript, small nuclear RNA, and small RNA u

250 Antisense transcription and ERI-1 binding to target RNAs

251 onal regulation, like alternative TSS usage, antisense transcription and exon splicing.

252 arity because of strongly enhanced divergent antisense transcription at promoters.

253 a13 domain relies on an enhancer that drives antisense transcription at the Hoxa11 locus after activa

254 In eukaryotes, antisense transcription can regulate sense transcription

255 AFs have also been recently found to enhance antisense transcription from the 3' end of the GAL10 cod

256 t sense transcription did not interfere with antisense transcription from the 3' LTR and vice versa,

257 Spt5 depletion also results in widespread antisense transcription initiating within this barrier r

258 argeted recruitment of NuA4 KAT to the GAL10 antisense transcription initiation site promotes GAL10 a

259 e that recruits Reb1p activator to the GAL10 antisense transcription initiation site.

260 f the ribosomal protein genes, TAF-dependent antisense transcription of GAL10 also requires NuA4 KAT.

261 e first time that a virus induces widespread antisense transcription of the host cell genome.

262 nally, we show that the enhancer that drives antisense transcription of the mouse Hoxa11 gene is abse

263 Single-cell analyses revealed that antisense transcription predominates in the absence of T

264 as9 targeting to the non-template strand for antisense transcription results in antisense transcripti

265 trand for antisense transcription results in antisense transcription termination, premature terminati

266 Antisense transcription through genic regions is pervasi

267 ts hundreds of transcripts from loci without antisense transcription to regulate RNA stability.

268 chromatin regulatory factors in controlling antisense transcription, thus illuminating chromatin reg

269 ion of sense transcription without affecting antisense transcription, which may be important for long

270 one H2B ubiquitin conjugase facilitate GAL10 antisense transcription, while the Swi/Snf and SAGA chro

271 f a primary molecule by uridylation-induced, antisense transcription-controlled 3'-5' exonucleolytic

272 ern the decision between sense and divergent antisense transcription.

273 genetic interventions for studying pervasive antisense transcription.

274 transcription initiation site promotes GAL10 antisense transcription.

275 n, thus illuminating chromatin regulation of antisense transcription.

276 r results indicate that, among the sense and antisense transcriptomes of these organs, the sense tran

277 We are studying the role of antisense transcripts (COOLAIR) in the cold-induced, epi

278 Natural antisense transcripts (NATs) are a prominent and complex

279 Furthermore, we discovered that natural antisense transcripts (NATs) frequently have actively tr

280 ng noncoding RNAs (lncRNAs) that are natural antisense transcripts (NATs) to transcripts encoding cen

281 d transcript isoforms, including eight novel antisense transcripts and their isoforms, as well as a n

282 HSV-1-induced and constitutively transcribed antisense transcripts are highly similar, indicating tha

283 We demonstrate that while sense and antisense transcripts can co-occur in the same cell they

284 larly evident among pathways showing natural antisense transcripts expression.

285 t HSV-1 induces the expression of about 1000 antisense transcripts from the human host cell genome.

286 n at TEs, resulting in an abundance of sense/antisense transcripts leading to high levels of ARGONAUT

287 In contrast, increased level of FLG antisense transcripts measured by probe A_21_P0014075 wa

288 Antisense transcripts originate either at gene promoters

289 Surprisingly, expression of sense and antisense transcripts produced by NAT pairs is significa

290 nsertion mutants reveal that they can act as antisense transcripts to repress expression levels of se

291 ive transcription, a genome-wide increase in antisense transcripts, and a rapid loss of viability of

292 t includes, for example, intergenic lncRNAs, antisense transcripts, and enhancer RNAs.

293 or ICP4 is sufficient to turn on a subset of antisense transcripts.

294 ism involving alternative polyadenylation of antisense transcripts.

295 te internodes, detected 12,621 sense and 995 antisense transcripts.

296 termination, thus generating novel sense and antisense transcripts.

297 tative primary piRNA transcripts overlapping antisense transposons.

298 Antisense treatment from birth with PMO25, increased lif

299 Antisense treatment to SMN2 intron7-splicing silencer (I

300 of SMA therapies, and systemically delivered antisense treatment, completely rescued liver pathology.